Ansell Limited (ASX:ANN) Announces Half Year Results and Interim Dividend
Ansell Limited (ASX:ANN) reports a 29.9% revenue increase for H1 and announces an interim dividend of 22.20 US cents per share.
Tag: Earnings Reports
PM Capital Global Opportunities Fund Limited (ASX:PGF) Announces Half-Year Financial Results
PM Capital Global Opportunities Fund Limited (ASX:PGF) announces a 3% revenue growth and 11% profit increase for the half-year ended December 2024.
Sigma Healthcare Limited (ASX:SIG) Upgrades FY25 EBIT Guidance
Sigma Healthcare (ASX:SIG) upgrades its FY25 EBIT guidance to $64-$70 million, driven by improved operational performance and strong contract execution.
DigitalX Limited (ASX:DCC) Reports January 2025 Treasury & Fund Update
DigitalX Limited (ASX:DCC) updates January 2025 treasury holdings and fund performance, highlighting increased Solana holdings and strong returns.
Pact Group Holdings Ltd (ASX:PGH) Responds to ASX Price Query
Pact Group Holdings Ltd (ASX:PGH) responds to ASX price query, outlining financial performance and upcoming half-year earnings release.
Spacetalk Ltd (ASX:SPA) Receives $428,853 R&D Tax Rebate
Spacetalk Ltd (ASX:SPA) receives a $428,853 R&D tax rebate, highlighting strong financial discipline and continued investment in product development.
Charter Hall Long WALE REIT (ASX:CLW) Announces 2025 Half Year Results
Charter Hall Long WALE REIT (ASX:CLW) reports strong financial performance and strategic portfolio updates in its 2025 half year results.
Domino’s Pizza Enterprises Limited (ASX:DMP) Announces H1 2025 Trading Update
Domino’s Pizza Enterprises Limited (ASX:DMP) announces its H1 2025 trading update, detailing store closures, financial performance, and dividend plans.
Charter Hall Long WALE REIT (ASX:CLW) Publishes 2025 Half Year Results
Charter Hall Long WALE REIT (ASX:CLW) announces its 2025 half-year results, highlighting stable financial performance and strategic portfolio developments.
Recce Pharmaceuticals Ltd (ASX:RCE) Corrects Quarterly Cash Flow Report
Recce Pharmaceuticals Ltd (ASX:RCE) corrects its Q4 2024 Cash Flow Report, reflecting positive net operating cash inflows.